The University of Virginia Comprehensive Cancer Center seeks participants ages 18 and over with acute myeloid leukemia or myelodysplasia with no circulating blasts for a research study. In this study, you will get the usual chemotherapy or in some cases, chemotherapy and radiation treatments for a transplant from a partially matched unrelated volunteer donor. You also will get medicines after transplant to help prevent graft versus host disease, one of the immune system complications after transplant. These medicines include tacrolimus, mycophenolate mofetil (MMF) and a lower dose of cyclophosphamide. The lower dose of post-transplant cyclophosphamide may reduce side effects of the drug and reduce infections after transplant. This study may also help doctors learn things that can help other people in the future.
The study involves pre transplant testing, a long inpatient admission, and several months of post transplant follow up. You will be on several medications post transplant and will need many outpatient visits. At the end of treatment, patients will be in long term follow up.
Additional information can be found here: https://www.clinicaltrials.gov/study/NCT06001385?spons=Center%20for%20I…